Insilico Completes Hundreds of Millions RMB Series C Financing to Accelerate Global Expansion and Innovation in R&D

Recently, Suzhou Inscinstech Intelligent Technology Co., Ltd. (“Inscinstech”) completed a Series C financing round amounting to hundreds of millions of yuan, led by the Service Trade Innovation Development Guidance Fund, with follow-on investments from Oriza Holdings and Inscinstech’s existing shareholder, Luxin Venture Capital Group Co., Ltd. This financing round marks another significant milestone in Inscinstech’s rapid development history. The funds will be allocated to innovative R&D for new product pipelines and the expansion of production capacity, providing strong momentum for Inscinstech’s global strategic layout in the biopharmaceutical sector.

Mr. Li Dawei, CEO of Inscinstech, stated, “First and foremost, we extend our sincere gratitude to the Service Trade Innovation Development Guidance Fund, Oriza Holdings, and Luxin Venture Capital Group Co., Ltd. for their recognition and support of Inscinstech. This not only affirms the achievements we have made but also provides strong momentum for our future high-speed growth. Looking ahead, Inscinstech will uphold its core philosophy and values of ‘Innovation-First,’ further strengthen the research and development of our core product pipeline applied in the health sciences sector, and enhance our competitiveness on the international stage through a global market expansion strategy. We look forward to joining hands with more domestic and international partners to jointly promote technological innovation and progress in the industry.””

Since its inception, Inscinstech has been committed to becoming a global leading service provider in the health sciences sector. Leveraging robust R&D capabilities and continuous technological innovation, the company has successively launched a series of innovative products that reach internationally leading standards. These include nucleic acid synthesizers, bioreactors, chromatography systems, tangential flow filtration systems, nanomedicine preparation systems, high-performance liquid chromatography (HPLC), and other process equipment and analytical instruments. Its product portfolio covers all key stages from high-throughput screening, laboratory-scale, and pilot-scale to commercial production, providing customers in the global biopharmaceutical, life sciences, healthcare, environmental protection, medical aesthetics, and food safety industries with comprehensive end-to-end solutions and efficient, professional services from R&D to manufacturing.

Inscinstech remains committed to a customer-centric approach, continuously optimizing product performance and service quality to deliver efficient and reliable solutions for industry clients. These solutions help enhance R&D and production efficiency, reduce costs, and accelerate time-to-market. Looking ahead, Inscinstech will continue to drive innovation through technological advancement, fostering high-quality development in the biopharmaceutical industry and contributing to the prosperity and progress of global health initiatives.

The Service Trade Innovation and Development Guidance Fund (hereinafter referred to as the “National Service Trade Fund”) is a national-level fund approved by the State Council and jointly initiated by the Ministry of Finance, the Ministry of Commerce, and China Merchants Group, with a total scale of RMB 30 billion.

The National Trade in Services Fund operates on a market-oriented basis through the model of “fund-of-funds equity participation in sub-funds + direct investment by the fund-of-funds.” First, it increases capital contributions to and establishes new private investment funds focused on sectors related to trade in services. Second, it allocates a portion of its capital for direct investment in trade-in-services enterprises that meet specified criteria.

The National Trade in Services Fund focuses its investments on the key areas specified in the Guiding Catalogue for Key Areas of Service Exports and the Guiding Catalogue for Key Development Areas of the Service Outsourcing Industry. It implements the requirements set forth in the Opinions of the General Office of the State Council on Accelerating the Development of New Formats and Models of Foreign Trade (Guo Ban Fa [2021] No. 24), supporting the cultivation of new formats and models of foreign trade, including service trade enterprises in sectors such as the health industry, cross-border e-commerce and logistics, and the digital economy.

Oriza Holdings has focused on the equity investment sector since its establishment in 2001. With assets under management exceeding RMB 100 billion, it is one of China’s leading equity investment firms. Since its inception, the company has prioritized investment opportunities in emerging industries such as integrated circuits, biopharmaceuticals, artificial intelligence, nanotechnology applications, cloud computing, and big data, while remaining committed to supporting the real economy and promoting industrial transformation and upgrading. To date, it has made direct investments in over 1,500 projects, and its fund-of-funds platform has invested in more than 180 subsidiary funds.

Luxin Venture Capital (Stock Code: 600783.SH), a subsidiary of Luxin Group, is the earliest-established professional venture capital institution in Shandong Province and one of the most influential in China. It is the first venture capital firm listed on China’s securities market and serves as a co-chair unit of the Equity and Venture Capital Professional Committee of the Investment Association of China.Focusing on national strategic emerging industries such as next-generation information technology, high-end equipment manufacturing, life sciences, new energy, new materials, aerospace, and green low-carbon development, Luxin Venture Capital prioritizes disruptive innovations, breakthroughs in critical “chokehold” technologies, and domestic substitution projects.Over the past two decades since its establishment, Luxin Venture Capital has invested in more than 300 companies, manages funds with a total scale exceeding RMB 20 billion, and has helped over 40 portfolio companies list on major domestic and international capital markets. Among its investments are more than 110 “Specialized, Refined, Differential, and Innovative” (SRDI) enterprises.In the healthcare and life sciences sector, Luxin Venture Capital and its affiliated funds have invested in over 40 projects, with a cumulative investment amount exceeding RMB 2 billion. Its notable portfolio companies include Keyuan Pharmaceutical, RemeGen, 3D Medicines, Silicon-based Bionics, Zhongke New Life, ABclonal, Vimai Medical, Baize Medical, Dapu Biological, and Bonatech.

Inscinstech, established in 2017, specializes in providing integrated solutions for biopharmaceutical CMC (Chemistry, Manufacturing, and Controls), spanning upstream and downstream processes to laboratory analysis. Leveraging its exceptional innovation capabilities and professional expertise, the company has been honored with numerous prestigious titles, including National Specialized, Refined, Differential, and Innovative SME, Suzhou Unicorn Enterprise, Suzhou Gazelle Enterprise, Municipal Engineering Research Center, and High-Tech Enterprise, underscoring its leading position in the industry.

Inscinstech has established two major R&D centers in Suzhou and Beijing, assembling a world-class R&D technical team whose core members hail from leading global enterprises in the life sciences instrumentation sector. The company operates a 10,000+ m² intelligent manufacturing base in Suzhou, ensuring product quality and rapid delivery.

To better serve global customers, Inscinstech has established branch offices in Beijing, Shanghai, Guangzhou, Wuhan, Chengdu, Hangzhou, and other cities, and set up a Global Operations Center in North America. Leveraging its robust sales network and professional technical service team, the company provides efficient, high-quality services to customers worldwide and responds swiftly to market demands.

Inscinstech has established collaborations with over 1,000 clients domestically and internationally. Its client base encompasses enterprises, universities, and research institutes in biomedical fields such as antibodies, vaccines, cell and gene therapy (CGT), nucleic acid drugs, and in vitro diagnostics (IVD). Furthermore, Inscinstech has forged deep strategic partnerships with key clients both in China and abroad, jointly driving the development and innovation of the biopharmaceutical industry.